Seattle Genetics Reports Third Quarter 2013 Financial Results
Autor: | Seattle Genetics, Inc. |
---|---|
Zdroj: | Business Wire (English). 11/05/2013. |
Abstrakt: | Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the third quarter and nine months ended September 30, 2013. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities, progress with its antibody-drug conjugate (ADC) pipeline, collaborator updates and upcoming milestones. [ABSTRACT FROM PUBLISHER] |
Databáze: | Regional Business News |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |